Truist analyst Robyn Karnauskas raised the firm’s price target on Eli Lilly to $430 from $421 and keeps a Buy rating on the shares after its Q1 results. The analyst notes that the investor focus remains on Mounjaro, which reported sales of $568.5M vs. expected $387M, and with the positive SURMOUNT-2 data in obese patients with Type 2 diabetes announced earlier, Truist is raising its Mounjaro peak 2032 sales estimates to $33B from $25B.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly price target raised to $485 from $432 at Cantor Fitzgerald
- Eli Lilly price target raised to $420 from $400 at Credit Suisse
- Eli Lilly price target raised to $430 from $400 at JPMorgan
- Eli Lilly price target raised to $447 from $438 at UBS
- Eli Lilly price target raised to $440 from $375 at Wells Fargo
